MouhammedAmirHabraMD
Endocrinology • Houston, TXAdrenal Disease, Diabetes, Osteoporosis & Bone Metabolism Medicine, Thyroid
Professor
Dr. Habra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 302-628-8357
Summary
- I am an oncologic endocrinologist at MD Anderson Cancer Center.
My clinical practice focuses on endocrine tumors and endocrine complications in cancer patients with special interest in adrenal and thyroid tumors.
Education & Training
Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2005
University of Missouri-ColumbiaResidency, Internal Medicine, 1999 - 2002
University of Aleppo Faculty of MedicineClass of 1995
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2026
TN State Medical License 2024 - 2026
WA State Medical License 2024 - 2026
GA State Medical License 2024 - 2025
LA State Medical License 2024 - 2025
MS State Medical License 2024 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- Join now to see all
Clinical Trials
- Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Start of enrollment: 2018 Feb 26
- Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Start of enrollment: 2018 Aug 20
- A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Start of enrollment: 2023 Mar 23
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 92 citationsPhase 2 study of pembrolizumab in patients with advanced rare cancers.Aung Naing, Funda Meric-Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar
Journal for Immunotherapy of Cancer. 2020-03-01 - 83 citationsComprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.Siyuan Zheng, Andrew D Cherniack, Ninad Dewal, Richard A Moffitt, Ludmila Danilova
Cancer Cell. 2016-05-09 - 17 citationsEndocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?Camilo Jimenez, Gustavo Armaiz-Pena, Patricia L M Dahia, Yang Lu, Rodrigo A Toledo
Cancers. 2022-01-18
Press Mentions
Management of Adrenocortical CarcinomaApril 10th, 2019
Lenvatinib Shows Promise for Patients with Radioiodine-Refractory Thyroid CancerFebruary 12th, 2015
A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy After Primary Surgical Resection in Patients with Adrenocortical Carcinoma, "Beyond the Abstract," by Mouhammed Amir Habra, MDFebruary 28th, 2013- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Member
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
